Peg-interferon improves liver histology in patients with HBeAg-positive chronic hepatitis B: No additional benefit of combination with lamivudine

Monika van Zonneveld, Pieter E. Zondervan, Yilmaz Cakaloglu, Christopher Simon, Ulus S. Akarca, Thomas M K So, Hajo J. Flink, Robert A. de Man, Solko W. Schalm, Harry L A Janssen, H. G M Niesters, B. Hansen, B. C M Vroom, C. M J van Nieuwkerk, R. A. de Vries, J. Jansen, J. Drenth, S. J. van den Hazel, J. W. den Ouden-Muller, A. C. TanD. M. Adler, P. Michielsen, H. van Vlierberghe, F. Nevens, J. Delwaide, J. Henrion, S. Zeuzem, G. Gerken, S. Bein, U. Treichel, J. Trojan, M. P. Manns, J. Hadem, J. Niederau, M. R. Buhl, I. M. Hansen, K. Krogsgaard, J. Cianciara, J. Jablonska, J. Kozlowska, D. Prokopowicz, R. Flisiak, T. Mach, M. Buti, A. Valdes, R. Esteban, M. Rodriguez, M. Garcia Espiga, A. Andriulli, G. Stornaiulo, G. B. Gaeta, G. Montalto, F. D'Antona, G. E. Kitis, P. Xiarchos Panagiotis, N. C. Tassopoulos, G. Ersöz, S. Karayalcin, C. Yurdayin, H. Bozkaya, H. Simsek, Y. Balaban, H. Senturk, F. Tabak, Y. Lurie, J. Heathcote, S. V. Feinman, S. Greenbloom, D. A. Sulaiman, R. Guan, I. Merican

Research output: Contribution to journalArticle

35 Citations (Scopus)

Abstract

Background: The effect of pegylated interferon or its combination with lamivudine on liver histology of patients with chronic hepatitis B (CHB) is unknown. In a double-blinded, randomized, multi-center study we assessed histological changes in 110 hepatitis B e-antigen (HBeAg)-positive CHB patients treated for 52 weeks with Pegylated interferon α-2b (PEG-IFN) in combination with either lamivudine or placebo. Liver biopsies were taken before and at the end of treatment. All biopsies were blinded and scored according to the Ishak system. Results: Necroinflammatory score improved (defined as a decrease of at least two points) in 25 patients (48%) of the PEG-IFN/lamivudine combination therapy group and in 31 patients (53%) of the PEG-IFN monotherapy group. The fibrosis score improved (decrease of at least 1 point) in 17 patients (33%) of the combination therapy group vs. 13 patients (22%) of the PEG-IFN monotherapy group (P=0.23). Responders (n=42), defined as serum HBeAg negative at the end of therapy, showed a larger decline in necroinflammatory score than non-responders (mean decline 2.3 and 1.2 pointsm respectively, P=0.02). Among patients receiving PEG-IFN monotherapy necroinflammation improved more frequently in responders (78% responders vs. 43% of non-responders, P=0.01) and in patients who showed normalization of ALT (76% of patients with normal ALT vs. 40% of patients with abnormal ALT, P = 0.01). Fibrosis score in the PEG-IFN monotherapy group improved more often in responders (39%) than in non-responders (15%, P=0.04). In the PEG-IFN/lamivudine combination therapy group, we found no signigficant association between virological and biochemical endpoints and histological improvement. Conclusion: Treatment with PEG-IFN therapy improves liver necroinflammation in HBeAg-positive CHB patients, particularly in responders to therapy. PEG-IFN also improves fibrosis in responders. Addition of lamivudine to PEG-IFN did not further improve the histological outcome.

Original languageEnglish
Pages (from-to)399-405
Number of pages7
JournalLiver International
Volume26
Issue number4
DOIs
Publication statusPublished - May 2006

Fingerprint

Lamivudine
Hepatitis B e Antigens
Chronic Hepatitis B
Interferons
Histology
Liver
Group Psychotherapy
Fibrosis
Biopsy
Therapeutics
Placebos

Keywords

  • Fibrosis
  • HBV
  • Liver inflammation
  • Pegylated interferon
  • Therapy

ASJC Scopus subject areas

  • Hepatology

Cite this

Peg-interferon improves liver histology in patients with HBeAg-positive chronic hepatitis B : No additional benefit of combination with lamivudine. / van Zonneveld, Monika; Zondervan, Pieter E.; Cakaloglu, Yilmaz; Simon, Christopher; Akarca, Ulus S.; So, Thomas M K; Flink, Hajo J.; de Man, Robert A.; Schalm, Solko W.; Janssen, Harry L A; Niesters, H. G M; Hansen, B.; Vroom, B. C M; van Nieuwkerk, C. M J; de Vries, R. A.; Jansen, J.; Drenth, J.; van den Hazel, S. J.; den Ouden-Muller, J. W.; Tan, A. C.; Adler, D. M.; Michielsen, P.; van Vlierberghe, H.; Nevens, F.; Delwaide, J.; Henrion, J.; Zeuzem, S.; Gerken, G.; Bein, S.; Treichel, U.; Trojan, J.; Manns, M. P.; Hadem, J.; Niederau, J.; Buhl, M. R.; Hansen, I. M.; Krogsgaard, K.; Cianciara, J.; Jablonska, J.; Kozlowska, J.; Prokopowicz, D.; Flisiak, R.; Mach, T.; Buti, M.; Valdes, A.; Esteban, R.; Rodriguez, M.; Garcia Espiga, M.; Andriulli, A.; Stornaiulo, G.; Gaeta, G. B.; Montalto, G.; D'Antona, F.; Kitis, G. E.; Xiarchos Panagiotis, P.; Tassopoulos, N. C.; Ersöz, G.; Karayalcin, S.; Yurdayin, C.; Bozkaya, H.; Simsek, H.; Balaban, Y.; Senturk, H.; Tabak, F.; Lurie, Y.; Heathcote, J.; Feinman, S. V.; Greenbloom, S.; Sulaiman, D. A.; Guan, R.; Merican, I.

In: Liver International, Vol. 26, No. 4, 05.2006, p. 399-405.

Research output: Contribution to journalArticle

van Zonneveld, M, Zondervan, PE, Cakaloglu, Y, Simon, C, Akarca, US, So, TMK, Flink, HJ, de Man, RA, Schalm, SW, Janssen, HLA, Niesters, HGM, Hansen, B, Vroom, BCM, van Nieuwkerk, CMJ, de Vries, RA, Jansen, J, Drenth, J, van den Hazel, SJ, den Ouden-Muller, JW, Tan, AC, Adler, DM, Michielsen, P, van Vlierberghe, H, Nevens, F, Delwaide, J, Henrion, J, Zeuzem, S, Gerken, G, Bein, S, Treichel, U, Trojan, J, Manns, MP, Hadem, J, Niederau, J, Buhl, MR, Hansen, IM, Krogsgaard, K, Cianciara, J, Jablonska, J, Kozlowska, J, Prokopowicz, D, Flisiak, R, Mach, T, Buti, M, Valdes, A, Esteban, R, Rodriguez, M, Garcia Espiga, M, Andriulli, A, Stornaiulo, G, Gaeta, GB, Montalto, G, D'Antona, F, Kitis, GE, Xiarchos Panagiotis, P, Tassopoulos, NC, Ersöz, G, Karayalcin, S, Yurdayin, C, Bozkaya, H, Simsek, H, Balaban, Y, Senturk, H, Tabak, F, Lurie, Y, Heathcote, J, Feinman, SV, Greenbloom, S, Sulaiman, DA, Guan, R & Merican, I 2006, 'Peg-interferon improves liver histology in patients with HBeAg-positive chronic hepatitis B: No additional benefit of combination with lamivudine', Liver International, vol. 26, no. 4, pp. 399-405. https://doi.org/10.1111/j.1478-3231.2006.01257.x
van Zonneveld, Monika ; Zondervan, Pieter E. ; Cakaloglu, Yilmaz ; Simon, Christopher ; Akarca, Ulus S. ; So, Thomas M K ; Flink, Hajo J. ; de Man, Robert A. ; Schalm, Solko W. ; Janssen, Harry L A ; Niesters, H. G M ; Hansen, B. ; Vroom, B. C M ; van Nieuwkerk, C. M J ; de Vries, R. A. ; Jansen, J. ; Drenth, J. ; van den Hazel, S. J. ; den Ouden-Muller, J. W. ; Tan, A. C. ; Adler, D. M. ; Michielsen, P. ; van Vlierberghe, H. ; Nevens, F. ; Delwaide, J. ; Henrion, J. ; Zeuzem, S. ; Gerken, G. ; Bein, S. ; Treichel, U. ; Trojan, J. ; Manns, M. P. ; Hadem, J. ; Niederau, J. ; Buhl, M. R. ; Hansen, I. M. ; Krogsgaard, K. ; Cianciara, J. ; Jablonska, J. ; Kozlowska, J. ; Prokopowicz, D. ; Flisiak, R. ; Mach, T. ; Buti, M. ; Valdes, A. ; Esteban, R. ; Rodriguez, M. ; Garcia Espiga, M. ; Andriulli, A. ; Stornaiulo, G. ; Gaeta, G. B. ; Montalto, G. ; D'Antona, F. ; Kitis, G. E. ; Xiarchos Panagiotis, P. ; Tassopoulos, N. C. ; Ersöz, G. ; Karayalcin, S. ; Yurdayin, C. ; Bozkaya, H. ; Simsek, H. ; Balaban, Y. ; Senturk, H. ; Tabak, F. ; Lurie, Y. ; Heathcote, J. ; Feinman, S. V. ; Greenbloom, S. ; Sulaiman, D. A. ; Guan, R. ; Merican, I. / Peg-interferon improves liver histology in patients with HBeAg-positive chronic hepatitis B : No additional benefit of combination with lamivudine. In: Liver International. 2006 ; Vol. 26, No. 4. pp. 399-405.
@article{4c2f9de6adc84df6873fcadb16c98b98,
title = "Peg-interferon improves liver histology in patients with HBeAg-positive chronic hepatitis B: No additional benefit of combination with lamivudine",
abstract = "Background: The effect of pegylated interferon or its combination with lamivudine on liver histology of patients with chronic hepatitis B (CHB) is unknown. In a double-blinded, randomized, multi-center study we assessed histological changes in 110 hepatitis B e-antigen (HBeAg)-positive CHB patients treated for 52 weeks with Pegylated interferon α-2b (PEG-IFN) in combination with either lamivudine or placebo. Liver biopsies were taken before and at the end of treatment. All biopsies were blinded and scored according to the Ishak system. Results: Necroinflammatory score improved (defined as a decrease of at least two points) in 25 patients (48{\%}) of the PEG-IFN/lamivudine combination therapy group and in 31 patients (53{\%}) of the PEG-IFN monotherapy group. The fibrosis score improved (decrease of at least 1 point) in 17 patients (33{\%}) of the combination therapy group vs. 13 patients (22{\%}) of the PEG-IFN monotherapy group (P=0.23). Responders (n=42), defined as serum HBeAg negative at the end of therapy, showed a larger decline in necroinflammatory score than non-responders (mean decline 2.3 and 1.2 pointsm respectively, P=0.02). Among patients receiving PEG-IFN monotherapy necroinflammation improved more frequently in responders (78{\%} responders vs. 43{\%} of non-responders, P=0.01) and in patients who showed normalization of ALT (76{\%} of patients with normal ALT vs. 40{\%} of patients with abnormal ALT, P = 0.01). Fibrosis score in the PEG-IFN monotherapy group improved more often in responders (39{\%}) than in non-responders (15{\%}, P=0.04). In the PEG-IFN/lamivudine combination therapy group, we found no signigficant association between virological and biochemical endpoints and histological improvement. Conclusion: Treatment with PEG-IFN therapy improves liver necroinflammation in HBeAg-positive CHB patients, particularly in responders to therapy. PEG-IFN also improves fibrosis in responders. Addition of lamivudine to PEG-IFN did not further improve the histological outcome.",
keywords = "Fibrosis, HBV, Liver inflammation, Pegylated interferon, Therapy",
author = "{van Zonneveld}, Monika and Zondervan, {Pieter E.} and Yilmaz Cakaloglu and Christopher Simon and Akarca, {Ulus S.} and So, {Thomas M K} and Flink, {Hajo J.} and {de Man}, {Robert A.} and Schalm, {Solko W.} and Janssen, {Harry L A} and Niesters, {H. G M} and B. Hansen and Vroom, {B. C M} and {van Nieuwkerk}, {C. M J} and {de Vries}, {R. A.} and J. Jansen and J. Drenth and {van den Hazel}, {S. J.} and {den Ouden-Muller}, {J. W.} and Tan, {A. C.} and Adler, {D. M.} and P. Michielsen and {van Vlierberghe}, H. and F. Nevens and J. Delwaide and J. Henrion and S. Zeuzem and G. Gerken and S. Bein and U. Treichel and J. Trojan and Manns, {M. P.} and J. Hadem and J. Niederau and Buhl, {M. R.} and Hansen, {I. M.} and K. Krogsgaard and J. Cianciara and J. Jablonska and J. Kozlowska and D. Prokopowicz and R. Flisiak and T. Mach and M. Buti and A. Valdes and R. Esteban and M. Rodriguez and {Garcia Espiga}, M. and A. Andriulli and G. Stornaiulo and Gaeta, {G. B.} and G. Montalto and F. D'Antona and Kitis, {G. E.} and {Xiarchos Panagiotis}, P. and Tassopoulos, {N. C.} and G. Ers{\"o}z and S. Karayalcin and C. Yurdayin and H. Bozkaya and H. Simsek and Y. Balaban and H. Senturk and F. Tabak and Y. Lurie and J. Heathcote and Feinman, {S. V.} and S. Greenbloom and Sulaiman, {D. A.} and R. Guan and I. Merican",
year = "2006",
month = "5",
doi = "10.1111/j.1478-3231.2006.01257.x",
language = "English",
volume = "26",
pages = "399--405",
journal = "Liver International",
issn = "1478-3223",
publisher = "Wiley-Blackwell Publishing Ltd",
number = "4",

}

TY - JOUR

T1 - Peg-interferon improves liver histology in patients with HBeAg-positive chronic hepatitis B

T2 - No additional benefit of combination with lamivudine

AU - van Zonneveld, Monika

AU - Zondervan, Pieter E.

AU - Cakaloglu, Yilmaz

AU - Simon, Christopher

AU - Akarca, Ulus S.

AU - So, Thomas M K

AU - Flink, Hajo J.

AU - de Man, Robert A.

AU - Schalm, Solko W.

AU - Janssen, Harry L A

AU - Niesters, H. G M

AU - Hansen, B.

AU - Vroom, B. C M

AU - van Nieuwkerk, C. M J

AU - de Vries, R. A.

AU - Jansen, J.

AU - Drenth, J.

AU - van den Hazel, S. J.

AU - den Ouden-Muller, J. W.

AU - Tan, A. C.

AU - Adler, D. M.

AU - Michielsen, P.

AU - van Vlierberghe, H.

AU - Nevens, F.

AU - Delwaide, J.

AU - Henrion, J.

AU - Zeuzem, S.

AU - Gerken, G.

AU - Bein, S.

AU - Treichel, U.

AU - Trojan, J.

AU - Manns, M. P.

AU - Hadem, J.

AU - Niederau, J.

AU - Buhl, M. R.

AU - Hansen, I. M.

AU - Krogsgaard, K.

AU - Cianciara, J.

AU - Jablonska, J.

AU - Kozlowska, J.

AU - Prokopowicz, D.

AU - Flisiak, R.

AU - Mach, T.

AU - Buti, M.

AU - Valdes, A.

AU - Esteban, R.

AU - Rodriguez, M.

AU - Garcia Espiga, M.

AU - Andriulli, A.

AU - Stornaiulo, G.

AU - Gaeta, G. B.

AU - Montalto, G.

AU - D'Antona, F.

AU - Kitis, G. E.

AU - Xiarchos Panagiotis, P.

AU - Tassopoulos, N. C.

AU - Ersöz, G.

AU - Karayalcin, S.

AU - Yurdayin, C.

AU - Bozkaya, H.

AU - Simsek, H.

AU - Balaban, Y.

AU - Senturk, H.

AU - Tabak, F.

AU - Lurie, Y.

AU - Heathcote, J.

AU - Feinman, S. V.

AU - Greenbloom, S.

AU - Sulaiman, D. A.

AU - Guan, R.

AU - Merican, I.

PY - 2006/5

Y1 - 2006/5

N2 - Background: The effect of pegylated interferon or its combination with lamivudine on liver histology of patients with chronic hepatitis B (CHB) is unknown. In a double-blinded, randomized, multi-center study we assessed histological changes in 110 hepatitis B e-antigen (HBeAg)-positive CHB patients treated for 52 weeks with Pegylated interferon α-2b (PEG-IFN) in combination with either lamivudine or placebo. Liver biopsies were taken before and at the end of treatment. All biopsies were blinded and scored according to the Ishak system. Results: Necroinflammatory score improved (defined as a decrease of at least two points) in 25 patients (48%) of the PEG-IFN/lamivudine combination therapy group and in 31 patients (53%) of the PEG-IFN monotherapy group. The fibrosis score improved (decrease of at least 1 point) in 17 patients (33%) of the combination therapy group vs. 13 patients (22%) of the PEG-IFN monotherapy group (P=0.23). Responders (n=42), defined as serum HBeAg negative at the end of therapy, showed a larger decline in necroinflammatory score than non-responders (mean decline 2.3 and 1.2 pointsm respectively, P=0.02). Among patients receiving PEG-IFN monotherapy necroinflammation improved more frequently in responders (78% responders vs. 43% of non-responders, P=0.01) and in patients who showed normalization of ALT (76% of patients with normal ALT vs. 40% of patients with abnormal ALT, P = 0.01). Fibrosis score in the PEG-IFN monotherapy group improved more often in responders (39%) than in non-responders (15%, P=0.04). In the PEG-IFN/lamivudine combination therapy group, we found no signigficant association between virological and biochemical endpoints and histological improvement. Conclusion: Treatment with PEG-IFN therapy improves liver necroinflammation in HBeAg-positive CHB patients, particularly in responders to therapy. PEG-IFN also improves fibrosis in responders. Addition of lamivudine to PEG-IFN did not further improve the histological outcome.

AB - Background: The effect of pegylated interferon or its combination with lamivudine on liver histology of patients with chronic hepatitis B (CHB) is unknown. In a double-blinded, randomized, multi-center study we assessed histological changes in 110 hepatitis B e-antigen (HBeAg)-positive CHB patients treated for 52 weeks with Pegylated interferon α-2b (PEG-IFN) in combination with either lamivudine or placebo. Liver biopsies were taken before and at the end of treatment. All biopsies were blinded and scored according to the Ishak system. Results: Necroinflammatory score improved (defined as a decrease of at least two points) in 25 patients (48%) of the PEG-IFN/lamivudine combination therapy group and in 31 patients (53%) of the PEG-IFN monotherapy group. The fibrosis score improved (decrease of at least 1 point) in 17 patients (33%) of the combination therapy group vs. 13 patients (22%) of the PEG-IFN monotherapy group (P=0.23). Responders (n=42), defined as serum HBeAg negative at the end of therapy, showed a larger decline in necroinflammatory score than non-responders (mean decline 2.3 and 1.2 pointsm respectively, P=0.02). Among patients receiving PEG-IFN monotherapy necroinflammation improved more frequently in responders (78% responders vs. 43% of non-responders, P=0.01) and in patients who showed normalization of ALT (76% of patients with normal ALT vs. 40% of patients with abnormal ALT, P = 0.01). Fibrosis score in the PEG-IFN monotherapy group improved more often in responders (39%) than in non-responders (15%, P=0.04). In the PEG-IFN/lamivudine combination therapy group, we found no signigficant association between virological and biochemical endpoints and histological improvement. Conclusion: Treatment with PEG-IFN therapy improves liver necroinflammation in HBeAg-positive CHB patients, particularly in responders to therapy. PEG-IFN also improves fibrosis in responders. Addition of lamivudine to PEG-IFN did not further improve the histological outcome.

KW - Fibrosis

KW - HBV

KW - Liver inflammation

KW - Pegylated interferon

KW - Therapy

UR - http://www.scopus.com/inward/record.url?scp=33645730480&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33645730480&partnerID=8YFLogxK

U2 - 10.1111/j.1478-3231.2006.01257.x

DO - 10.1111/j.1478-3231.2006.01257.x

M3 - Article

C2 - 16629642

AN - SCOPUS:33645730480

VL - 26

SP - 399

EP - 405

JO - Liver International

JF - Liver International

SN - 1478-3223

IS - 4

ER -